Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
(1) Evaluate the efficacy of apatinib in combination with standard second-line chemotherapy
for advanced colorectal cancer. Whether it can prolong Progression Free Survival (PFS),
overall survival (OS) in patients with advanced colorectal cancer and reduce symptoms and
improve quality of life compared with standard second-line chemotherapy; (2) Observe the
safety of apatinib for the treatment of advanced colorectal cancer.